Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(30 sites) United States
Stanford Cancer Center, Palo Alto, California University of California San Francisco, San Francisco, California University of Miami, Miami, Florida Moffitt Cancer Center, Tampa, Florida Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia Indiana University Cancer Center, Indianapolis, Indiana University of Kansas Hospital Authority, Kansas City, Kansas Massachusetts General Hospital, Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts University of Michigan, Ann Arbor, Michigan Karmanos Cancer Institute, Detroit, Michigan Henry Ford Hospital, Detroit, Michigan Washington University, St Louis, Missouri Mount Sinai Hospital, New York, New York Memorial Sloan Kettering, New York, New York University of North Carolina At Chapel Hill, Chapel Hill, North Carolina Levine Cancer Institute, Charlotte, North Carolina Duke University Medical Center, Durham, North Carolina Cleveland Clinic, Cleveland, Ohio Ohio State University, Columbus, Ohio Oregon Health & Science University, Portland, Oregon University of Pennsylvania, Philadelphia, Pennsylvania Medical University of South Carolina, Charleston, South Carolina Sarah Cannon, Nashville, Tennessee Vanderbilt Medical Center, Nashville, Tennessee Baylor College of Medicine, Houston, Texas Virginia Commonwealth University, North Hospital, Richmond, Virginia Fred Hutchinson Cancer Research Center, Seattle, Washington University of Wisconsin, Madison, Wisconsin Medical College of Wisconsin, Milwaukee, Wisconsin